FDA Picks Seven Companies for Its Factory Fast-Lane Pilot: What Life Sciences Firms Should Know
The FDA selected seven companies for its PreCheck Pilot Program to speed new U.S. drug manufacturing facilities. Two chosen sites are in New York.
Building a drug manufacturing facility in the United States means years of regulatory navigation. The FDA just showed it is willing to make that road smoother for companies that engage early.
What happened
On June 29, 2026, the FDA announced it had selected seven companies for its PreCheck Pilot Program. The program offers participants earlier engagement with the FDA and a more predictable regulatory path for building new U.S. drug manufacturing facilities.
Demand was real: more than 80 companies applied for the seven spots. And there is a regional note for our corner of the country. Two of the chosen sites are in New York: Amneal on Long Island and Regeneron in Saratoga Springs, per the FDA's release. The full announcement is on the FDA's website.
What it means for you
If you are in life sciences, the signal is worth more than the program itself. The FDA is rewarding companies that come talk to the agency early about new U.S. facilities. Early engagement is being treated as a feature, not a formality.
This round is closed, so there is no application to rush. But the FDA says it will keep evaluating the program, which means future openings are possible. If a U.S. manufacturing facility is anywhere in your company's plans, even a few years out, it makes sense to watch this program and to think about what a strong application would look like before the next window opens. The companies that won spots this round almost certainly did not start preparing the week applications opened.
Even outside this pilot, the underlying lesson holds. Regulators reward preparation and early conversation. Showing up with a clear plan, organized documentation, and questions asked in advance tends to buy smoother reviews everywhere, not just at the FDA.
If your business is weighing a U.S. manufacturing move, this is a good moment to get your regulatory strategy and your contracts pointed in the same direction. Turley Law works with businesses on the contract and transaction side of growth plans and can coordinate with regulatory specialists where needed.
Source
Read the official announcement: FDA Selects Seven Participants for PreCheck Pilot Program.
Questions about how this affects your business? A consultation is $50 for 30 minutes, credited toward any flat-fee service.
This article is for general informational purposes only and is not legal advice.
Attorney Advertising. Prior results do not guarantee a similar outcome.